LatestInvestigational EGFR x HER3 Therapy Advances to Phase III Trial for Lung Cancer
Health

Extended-Interval Tarlatamab Dosing Shows Consistent Safety and Efficacy in Small Cell Lung Cancer

Extended-Interval Tarlatamab Dosing Shows Consistent Safety and Efficacy in Small Cell Lung Cancer
Cancer
Summary

New research from the Phase II DeLLphi-309 study demonstrates that extended-interval dosing of tarlatamab maintains consistent efficacy and safety profiles compared to the standard every-two-week treatment schedule for patients with previously treated small cell lung cancer. The findings, presented at the 2026 International Association for the Study of Lung Cancer World Conference, show comparable pharmacokinetic results across different dosing intervals. This development could potentially offer greater convenience and flexibility for patients managing this aggressive cancer type. Extended-interval dosing may reduce treatment burden while maintaining therapeutic effectiveness for SCLC patients.

Medical Xpress

Originally published on

Medical Xpress

Read full article(opens in new tab)

Fetched: September 12, 2026 at 10:00 AM

Related News

More news you might be interested in

View all
Investigational EGFR x HER3 Therapy Advances to Phase III Trial for Lung Cancer
Health
Cancer

Investigational EGFR x HER3 Therapy Advances to Phase III Trial for Lung Cancer

An investigational antibody-drug conjugate targeting EGFR and HER3 has demonstrated promising effectiveness and manageable side effects in patients with previously treated EGFR-mutated non-small cell lung cancer (NSCLC). Based on these positive results, researchers have selected the 2.5 mg/kg dose for further evaluation in the IZABRIGHT-Lung01 Phase III registrational study, a global clinical trial. This advancement represents progress in treating a subset of lung cancer patients who have developed resistance to prior therapies. The dual-targeting approach may offer improved outcomes for patients with specific genetic mutations. This milestone brings the therapy closer to potential regulatory approval and availability for eligible patients.

2 hours ago
Medical Xpress
Atezolizumab + Chemotherapy Doubles Event-Free Survival in Resectable Lung Cancer
Health
Cancer

Atezolizumab + Chemotherapy Doubles Event-Free Survival in Resectable Lung Cancer

Final results from the Phase III IMpower030 trial demonstrate that patients with resectable stage II–IIIB non-small cell lung cancer (NSCLC) receiving perioperative atezolizumab combined with platinum-based chemotherapy achieved a median event-free survival of 62.8 months, more than double the 34.9 months observed with chemotherapy alone. This immunotherapy-based approach represents a significant advancement in treating surgically resectable lung cancer, extending the time before disease progression or recurrence occurs. The combination strategy leverages atezolizumab's immune-checkpoint inhibition alongside traditional chemotherapy for enhanced treatment efficacy. These findings provide important therapeutic options for early-stage lung cancer patients and may reshape treatment protocols in oncology practices. The substantial survival benefit highlights the potential of perioperative immunotherapy in improving long-term outcomes for eligible patients with resectable disease.

2 hours ago
Medical Xpress
Local Consolidative Therapy Does Not Improve Survival in Metastatic Lung Cancer After Dual Immunotherapy
Health
Cancer

Local Consolidative Therapy Does Not Improve Survival in Metastatic Lung Cancer After Dual Immunotherapy

A major clinical trial presented at the IASLC 2026 World Conference found that adding local consolidative therapy (LCT) after treatment with nivolumab plus ipilimumab—two immunotherapy drugs—did not improve overall survival or progression-free survival in patients with metastatic non-small cell lung cancer (NSCLC). This finding applies even to patients with oligometastatic disease, a more limited form of metastatic cancer. The results suggest that for this patient population, dual immunotherapy alone may be sufficient, potentially sparing patients from additional invasive procedures. These findings could reshape treatment strategies and help oncologists make more informed decisions about which patients benefit from consolidative local treatments.

2 hours ago
Medical Xpress
Pumitamig Plus Ifinatamab Deruxtecan Shows Promise for Small Cell Lung Cancer
Health
Cancer

Pumitamig Plus Ifinatamab Deruxtecan Shows Promise for Small Cell Lung Cancer

An investigational drug combination of pumitamig and ifinatamab deruxtecan demonstrated encouraging early antitumor activity and manageable safety in patients with small cell lung cancer (SCLC), according to Phase Ib/II trial data presented at the 2026 IASLC World Conference on Lung Cancer. Small cell lung cancer is an aggressive form of lung cancer with limited treatment options, making new therapeutic approaches critical for patients. This early-stage trial represents a potential advancement in SCLC treatment, offering hope for improved outcomes in this challenging disease. The manageable safety profile is particularly important as it suggests the combination may be tolerable for patients requiring long-term therapy.

2 hours ago
Medical Xpress